Prognosis After Discontinued Treatment due to Immune-Related Adverse Events in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma.

IF 2.2 3区医学 Q1 OTORHINOLARYNGOLOGY

Head and Neck-Journal for the Sciences and Specialties of the Head and Neck Pub Date : 2025-09-12 DOI:10.1002/hed.70043

Hiromasa Ishihara, Yuki Asahi, Masashi Kuroki, Ken Saijo, Ryo Kawaura, Rina Kato, Manato Matsubara, Saki Akita, Tatsuhiko Yamada, Ryota Iinuma, Hiroshi Okuda, Hirofumi Shibata, Takenori Ogawa

{"title":"Prognosis After Discontinued Treatment due to Immune-Related Adverse Events in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma.","authors":"Hiromasa Ishihara, Yuki Asahi, Masashi Kuroki, Ken Saijo, Ryo Kawaura, Rina Kato, Manato Matsubara, Saki Akita, Tatsuhiko Yamada, Ryota Iinuma, Hiroshi Okuda, Hirofumi Shibata, Takenori Ogawa","doi":"10.1002/hed.70043","DOIUrl":null,"url":null,"abstract":"Background: The prognostic impact of immune-related adverse events (irAEs) in recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC) remains unclear, particularly after treatment discontinuation.Methods: This retrospective study included RM-HNSCC patients treated with nivolumab or pembrolizumab. The association between irAEs, treatment response, and prognosis was analyzed. To minimize immortal time bias, survival was assessed at multiple time points. Outcomes after permanent discontinuation due to irAEs were also evaluated.Results: Among 92 cases, 25 cases (27.2%) experienced irAEs. Cases that experienced irAEs showed better progression-free survival than those who did not experience irAEs. Eight cases permanently discontinued treatment due to irAEs, and six cases maintained tumor shrinkage after discontinuing ICI.Conclusions: In this study, irAEs were associated with a good prognosis. Furthermore, it was revealed that many of the cases in which treatment was permanently discontinued due to irAEs continued a durable response even after treatment ended.","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/hed.70043","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The prognostic impact of immune-related adverse events (irAEs) in recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC) remains unclear, particularly after treatment discontinuation.

Methods: This retrospective study included RM-HNSCC patients treated with nivolumab or pembrolizumab. The association between irAEs, treatment response, and prognosis was analyzed. To minimize immortal time bias, survival was assessed at multiple time points. Outcomes after permanent discontinuation due to irAEs were also evaluated.

Results: Among 92 cases, 25 cases (27.2%) experienced irAEs. Cases that experienced irAEs showed better progression-free survival than those who did not experience irAEs. Eight cases permanently discontinued treatment due to irAEs, and six cases maintained tumor shrinkage after discontinuing ICI.

Conclusions: In this study, irAEs were associated with a good prognosis. Furthermore, it was revealed that many of the cases in which treatment was permanently discontinued due to irAEs continued a durable response even after treatment ended.

查看原文本刊更多论文

复发性和转移性头颈部鳞状细胞癌因免疫相关不良事件而停止治疗后的预后。

背景：复发/转移性头颈部鳞状细胞癌（RM-HNSCC）的免疫相关不良事件（irAEs）对预后的影响尚不清楚，特别是在停止治疗后。方法：这项回顾性研究纳入了接受纳武单抗或派姆单抗治疗的RM-HNSCC患者。分析irAEs、治疗反应和预后之间的关系。为了最小化不朽时间偏差，在多个时间点评估生存。我们还评估了因irae而永久停药后的结果。结果：92例患者中有25例（27.2%）发生irae。经历irae的病例比没有经历irae的患者表现出更好的无进展生存期。8例因irAEs永久停药，6例停药后肿瘤仍保持缩小。结论：在本研究中，irAEs与良好的预后相关。此外，研究显示，许多因irae而永久停止治疗的病例即使在治疗结束后仍有持久的反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Head and Neck-Journal for the Sciences and Specialties of the Head and Neck 医学-耳鼻喉科学

CiteScore

7.00

自引率

6.90%

发文量

278

审稿时长

1.6 months

期刊介绍： Head & Neck is an international multidisciplinary publication of original contributions concerning the diagnosis and management of diseases of the head and neck. This area involves the overlapping interests and expertise of several surgical and medical specialties, including general surgery, neurosurgery, otolaryngology, plastic surgery, oral surgery, dermatology, ophthalmology, pathology, radiotherapy, medical oncology, and the corresponding basic sciences.